<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980197</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0274</org_study_id>
    <nct_id>NCT03980197</nct_id>
  </id_info>
  <brief_title>Strategy to Prevent Transmission of Multidrug-resistant Gram-negative Organisms in ICU</brief_title>
  <official_title>Strategy to Prevent Transmission of Multidrug-resistant Gram-negative Organisms in ICU - Evaluation of Effect of Active Surveillance Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sung-Han Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objective of study The purpose of this study was to investigate whether the active
           surveillance and preemptive isolation of multidrug-resistant Gram-negative bacteria in
           the intensive care unit affected the reduction of the rate of acquisition of multidrug-
           resistant Gram-negative bacteria (MDRGNB).

        2. Background Treatment option for MDRGNB (Carbapenem-resistant P. aeruginosa,
           Carbapenem-resistant A. baumannii, Carbapenem-resistant Enterobacteriaceae) is limited.
           Development of infection due to MDRGNB is common in ICU. Strategy to prevent
           transmission of MDRGNB is needed, and there is two approaches; First, antimicrobial
           stewardship program, and second, infection control strategy.The investigators aimed to
           figure out the role of active surveillance test and preemptive isolation of MDRGNB in
           reduction of acquisition rate of MDRGNB.

        3. Methods Pragmatic cluster randomized, crossover, controlled trial During first period (6
           months), intervention group (randomized 3 ICUs) perform daily chlorhexidine bathing,
           active surveillance test and preemptive isolation and contact precaution. Control group
           (randomized 3 ICUs) perform standard precaution with daily chlorhexidine bathing, and
           start contact precaution when clinical isolates reveals MDRGNB.

      After 1 month washout period, intervention group and control group cross over for next 6
      months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients who acquired MDRGNB in ICU per 1000 patient-days</measure>
    <time_frame>through study completion, an average 6 months</time_frame>
    <description>The number of patients who acquired MDRGNB in ICU per 1000 patient-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of bloodstream infection due to MDRGNB</measure>
    <time_frame>through study completion, an average 6 months</time_frame>
    <description>Rate of bloodstream infection due to MDRGNB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand hygiene compliance rates (%) of healthcare workers</measure>
    <time_frame>through study completion, an average 1 year</time_frame>
    <description>number of Hand hygiene compliance/number of opportunicities for hand hygiene of healthcare workers *100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of ICU stay</measure>
    <time_frame>through study completion, an average 6 months</time_frame>
    <description>Days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>28-days</time_frame>
    <description>28-day mortality rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active surveillance and preemptive isolation</intervention_name>
    <description>Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enroll all patients who admit to the ICUs during the study period

        Exclusion Criteria:

          -  Patients who discharge within 2 days after admission to ICUs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiwon Jung, MD</last_name>
    <phone>82-10-3010-5041</phone>
    <email>trueblue27@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung-Han Kim, MD</last_name>
    <phone>82-10-3010-3305</phone>
    <email>kimsunghanmd@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiwon Jung, MD</last_name>
      <phone>82-10-3010-5041</phone>
      <email>trueblue27@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Princiapl investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

